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© 201? Japanese Society of Tropical Medicine Abstract: The milestones marking substantial changes in the lives or in the survival of humans deserve to be
remembered. It has been only 11 years since we experienced an event that not even the most optimistic amongst
us would have predicted before 1997. Let us place the facts in time. At the beginning of the 80s, we faced the
distressing reality that more than three quarters of all children, men and women found to have antibodies directed
against a new infectious agent named human immune deficient virus (HIV) were bound to die. The mere reactivity
of the serum of a human being against a virus characterized in 1983 (antibodies) handed an almost inevitable sentence
of death. At that time the evolution of this viral infection was assessed by the quantification of a sub type of white
cells, the auxiliary lymphocytes or CD4. This count was the principal evidence for most of the predictions on how
a person might survive without degradation, and the value of such cells was the abacus used to forecast the time
when an individual would develop irreversible blindness, to anticipate respiratory failure, and to predict the time
before weakness would appear after devastating diarrhea, etc. We should recall that the CD4 cell count was even
used as a predictor of the initiation of cognitive shrinkage, forecasting dementia as well as the signs that would
take hold of personality as a consequence of infections or neoplastic transformations in the encephalitic mass.
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THE PREDICTIONS
From the early 1980s to 1997, the task of providing
assistance to HIV patients was perceived as futile. Health
care establishments worked to alleviate pain amid a wall of
resignation, receiving lab results in which the CD4 figures
(surrogate markers) helped nurses, auxiliaries, students and
doctors to hide their despair behind a protective fence built
with objective cell numbers.
Before 1997 the sensation of powerlessness was grip-
ping given that, aside from offering people with HIV the
possibility to be included in research protocols to evaluate
the primary or secondary prevention of opportunistic infec-
tions (pneumonia, encephalitis, retinitis, diarrhea), little
could be done to limit the devastation triggered by the viral
infection. The physician’s work was limited to the descrip-
tion and assessment of technical events related to prognosti-
cation (CD4 count, levels of beta two micro-globulin or the
intensity on the band of the protein P25 in the Western Blot
test). Between 1985 and 1997 the surrogate marker results
from the laboratories led to an attitude in the intimate forums
of physicians that, as though they were fond of sport bets
or prophecies, the circulating lymphocyte figures enabled
clinicians to “predict” death in 8 months or less in some, or
in less than 2 years in others cases.
At that time it caused constant distress trying to articu-
late the answer to the question of how, in the HIV infected
patient’s life, the decrease in CD4 cells creates a favorable
environment for life threatening infections, for the growth
of certain tumor masses and cancers of the immune system,
adding physical and moral wasting signs and lethal risks to
the pathology already triggered by this viral infection. The
predictions were expressed in the context of anguish suf-
fered by both patient and physician; the latter had to put into
words the eventuality of the former’s imminent and irre-
versible degradation.
When patients asked, “Now what should I do?” I recall
frequently listening to colleagues—who were hostages of
their own pessimism—provide answers loaded with syn-
tactic constructions in the style of: “arrange your papers,” or
“make your will,” or “seek advice with a lawyer,” or “call
your family and put your business in order.”
Before 1997, the health workers treating people infected
with HIV were overwhelmed with reservations about the
appropriateness of prescribing and verifying the results of
tests conceived to foretell physical degradation. In fact,
once the auguries were established by this crop of scientific
forecasts, no efficient therapeutics with long-term efficacy
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could be proposed. When treatments failed to protect the
HIV-infected individual from pneumocistosis, cytomegalo-
virus, toxoplasmosis or mycobacterium infections, all that
could be made to confront the immune collapse was to
encourage the person, without any certainty, to fight empiri-
cally for life. At that time, in a humanistic framework of
affection and understanding, it appeared even “helpful” to
evoke in words the imminent arrival of the end of life.
From the position of the infected persons, the surrogate
marker results were digested with resignation and fear,
probably because the specific peculiarities of the trans-
mission of this virus mixed guilt with suffering, and this
enhanced the experience of anguish and hopeless expecta-
tions. Because confidentiality had to be guaranteed, many
patients transformed suffering into inscrutability and silence.
This was palpable when making the rounds of hospital beds
where lonely human beings were coming to the end of their
lives in conditions of affective and physical abandonment.
TREATMENTS BEFORE 1997: STATE OF THE ART
Approaching 1997, neither alternative medicine, nor
macrobiotic diets, nor organic food, nor varied nutritive
complements or supplements overloaded with vitamins and
minerals, nor any kind of gym work or sport, nor sea water,
nor thermal stations, nor essential oils, nor Western or
Oriental massages, nor the consumption of oligoelements,
nor antioxidants, nor the “reorganization and harmonization
of the circulating energy of the body with that of the uni-
verse,” nor yoga, nor tae-kwon-do, nor the good vibes of
associative groups, nor witchcraft, nor transcendental medi-
tation, nor the alkaloids of Cannabis sativa in any prepara-
tion or route of administration, nor the products obtained
from Latin American cactus or fungi or exotic vegetables
from any continent, nor the systemic or ex-vivo administra-
tion of cytokines, nor interferons, nor growth hormones, nor
steroidal anabolic agents, nor heavy-metal associated organic
molecules, nor preparations obtained following the formulae
of Far Eastern or Western pharmacopoeias, nor passive
immune therapeutics with hyper immune gamma globulin
preparations, nor treatments with antigens of the virus, nor
auto vaccines, nor derivatives of human placenta, nor the
first antiretroviral strategies, exerted beneficial effects
either on immune regeneration or on the quality of life of
the infected persons, less even on the survival of the persons
who had received the “declaration” of AIDS.
EFFICACIOUS THERAPEUTICS
Optimism rose in 1997 when it was proven worldwide
that new antiviral strategies associating two or three synthetic
antiviral compounds could reduce the mortality due to
AIDS. In the United States the mortality decreased from
93% in 1981 to 6% at the end of 1997, and the follow up of
patients in Norway showed that the level of mortality
between 1986 and 1990 (47%) was dramatically decreased
after 2006.
Several other trials confirmed these results worldwide.
In Brazil it has been reported that the number of HIV infected
people who had undergone antiretroviral treatment needing
hospitalization and the number of deaths were significantly
reduced after 1997 (the Brazilian population started to
benefit from free antiretroviral therapeutics in 1996).
However, the number of infected persons infected increased,
indicating that access to free treatment requires consistent
additional efforts to educate the population regarding the
ways to avoid being contaminated by this virus.
In Barcelona, a constant increase in HIV-related
mortality was observed until 1995, but the mortality curve
showed and inflection and a significant decrease across
almost the whole population from 1997. In this city,
however, it should be noted that the treatments associated
with antiretrovirals do not show an equivalent efficacy
after stratifying the population according to the economic
resources of the different groups of patients: the reduction
in mortality was significantly lower in the layers of the
population with the fewest resources and in persons who
routinely intravenously inject psychoactive agents intra-
venously. Because in Spain the antiretroviral treatments are
free of charge, the free treatment is an element that, although
necessary to fight AIDS, does not sufficiently explain the
discrepancy of the results obtained on mortality. Hence, to
improve the quality of life and to prolong life expectancy,
the intrinsic capacity of the antivirals to act on the specific
molecular targets of the viral enzymes and the appropriate
oral bioavailability of the pharmaceutical preparations
should not be dissociated from other factors that determine
clinical efficacy. Patients should actively adhere to the treat-
ment and respect all the hourly indications (“compliance”),
while health workers should first of all construct patient
relationships which develop respect and affection with
bonds of confidence, and secondly should educate infected
and not-infected people alike, especially the population
with a low level of education.
The encouraging results remove any doubt that since
1997 (when the therapeutic strategy known as post-exposition
prophylaxis of the newborn baby was validated) antiretroviral
treatments have limited the transmission of HIV from
mothers to their babies due to a prominent reduction of the
viral load in the blood of progenitors. Moreover, the first
large studies conducted on pregnant women in 16 countries
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could be limited if appropriate treatments were administered
according to a specific dosage and schedule. Currently, the
levels of transmission of HIV from mother to child range
between 1 and 2% in highly industrialized countries, and the
benefits of antiretrovirals have been demonstrated among
toddlers with maternal milk as their only nutritional option.
THE AWAKENING OF DELUSIONS
The catastrophe triggered by AIDS became noticeable
in Western countries in the early 1980s, allowing certain
individuals to undertake simultaneously the function of judge,
jury, referee and contender. The newborn connoisseurs of
AIDS overran the scientific and medical scene, and from
this new arena they ruled the direction of work and qualified
the relevance and value of investigations: the ex-nihilo
structures played as unarguable commanders who decided
on the pertinence of tasks to be conducted and the kind of
information that deserved to be spread to society.
The rapid development of scientific leaders and state
machines during the first year of the emergent epidemic can
be viewed retrospectively as beneficial if this emanation
was followed by decisions leading to the improvement of
people’s health. However, what was produced during those
years reveals a picture in which AIDS only created—in
countries with highly public concerns regarding health and
socialized medicine—circles of power in which some
flocked to the state network, rapidly enhancing their own
careers and broadcasting their views as if they had received
supreme revelations and dogmas on the infections and their
evolution. This extensive occupancy of the chairs of AIDS
expertise both basic research and medical treatment brought
about quick and unexplained fame as well as the appoint-
ment of a legion of new medical professors. Those who in
other geographical contexts would have been labeled
“apparatchiks” made indisputable decisions regarding the
appropriateness of who, why, where and how all the work
related to AIDS research should be conducted.
During the first epidemic years, the investigation
concerns were largely centered on imposed visions. Today,
it deserves to be re-emphasized that the extent of human
and financial resources allowed researchers to show, among
others, the repeated issues imposing mycoplasma as the
essential cofactor that determined the progress of a viral
infection towards AIDS (today this processes are only
limited by the association of antivirals).
Moreover, the dubious clinical relevance of adminis-
tration of organic heavy metal salt complexes recalled and
analyzed, as well as the treatment with cortisone to limit
HIV evolution, or the benefits of palsmapheresis, or the
implications of the supreme determination of the last
identified lymphocyte or macrophage membrane associated
protein or receptor and the overriding implications of other
infectious agents different from HIV in the clinical degrada-
tion of people with HIV. It is amazing to realize that, at that
time, many of those holding the presupposed “knowledge
on AIDS” validated their work by their mere appearance in
the mass media, and it happened frequently that many of their
so-called truths were denied a posteriori.
As a paradigm of what was happening in science and
medicine during the first years of the AIDS epidemic in
France, generous donations for research were made to
governmental and non-governmental institutions as the result
of gifts flooding in from people with AIDS, most of whom
were dead as a consequence of ineffective therapeutics. In
addition, the cash influx to certain institutions increased
from the mid-1980s and the mid-1990s thanks to a signifi-
cant real estate patrimony that had been donated from
people dying from AIDS or those in the advanced phase of
infection who hoped that their gifts would contribute to the
remedy of AIDS and help to finance the development of a
vaccine. The citizens organized public performances,
spectacles, concerts, fairs, and other highly-covered media
events to raise funds for research to combat AIDS, and it
was in the 1980s and 1990s that some French public notary
waiting rooms kept pre-printed leaflets to be filled, dated
and signed by a person so that his/her assets could be
automatically transferred, posthumously, to organizations
promoting AIDS research.
However, the results obtained by the recipients of
these sums indicate that the expectations were not fulfilled
and those of us who were in permanent contact with AIDS
patients ask ourselves if the bequeathed assets have been
effectively utilized. Let’s remember that thanks to such
generosity important sums were raised but were used to
build facilities that did not fulfill the intentions of the legatee
or pay for buildings where the AIDS authorities and their
groups of followers might have expanded their ambitions.
Our intention here is not to criticize the quality of the results,
but the retrospective assessment of scientists’ activities shows
that the research was conceived, not only to approach the
objectives desired by the legatees, but also to facilitate
work in scientific areas which the researchers personally
considered interesting or entertaining.
Simultaneously, in the public hospitals, the funds
collected from generous donators and also from the national
budget for public health were spent for a so-called “machine
to produce papers”. In public infrastructures a significant
portion of the funding for work carried out in those years by
the staff (whose salaries came from the taxpayers) was
equivalent to what is offered for registration purposes by the
private clinical research organizations to pharmaceutical62 Tropical Medicine and Health Vol.39 No.2, 2011
corporations for phase II and phase III clinical trials. These
CRO-like activities conducted by the medical staff increased
the chances of civil servants or residents getting better posi-
tions, and at the bottom line, the health system built by the
believers in socialized medicine was articulated as a public
machine to feed resumes. Hence, this was also far from
what the donors expected. However, because neither policy
nor procedure taught at that time—when illness, suffering,
donators, altruism, and generosity were mixed with good
will—how to manage the funds, it seems senseless to accuse
anyone  a posteriori of inefficiency. Nevertheless, this
peculiar situation reveals that the towers of fallacy and
delusion which were built while struggling to reduce AIDS
suffering should be burned into the future to avoid pre-
cipitated decisions and new virtual creatio ex-nihilo estab-
lishments. The birth and rapid growth of the HIV centers
created an unfortunate picture that should be retained as a
pattern to predefine what should never be done again.
EFFICIENCY AND OPTIMISM AND THE EMER-
GENCE OF A PARADOX
AIDS generated a new unexpected ideological paradox
that was inconceivable before 1997. In fact, results show
that the HIV infection is no longer synonymous with a death
sentence and persons who endure the consequences of
bacterial, viral or parasitic infections in what was known as
“declared AIDS” may recover their immune functionalities
as well as their corporal mass and their aptitude to work, to
love and to create. In countries with health systems offering
free access to appropriate treatments, the lethal HIV infec-
tion has been transformed into a chronic controllable afflic-
tion. But none of these achievements were the result of
appropriate public research policies, either of the product
obtained from the avant-garde investigators who proved
while working in public institutions to be eager to face the
pertinent issues for the cure of AIDS, nor from acts of
altruism!
If the life of people living with HIV improved, this
was the result of the accurate, creative and systematic labors
of chemists, biologists and clinicians who were pushing
research forward from inside the pharmaceutical corpora-
tions, a statement that needs to be placed in the perspective
of our primitive cultural perception of the original actors
fighting against this infection. It appears today that not all
was pristine that was generated by honest civil servants in
their respective positions or that was the consequence of
public research policies.
The HIV paradox deserves to be pointed out because,
if since 1997 this viral infection is no longer synonymous
with a death sentence, it is due almost solely to those who
were considered to be unscrupulous “merchants of health”.
The pharmaceutical industry was stigmatized and
labeled as deprived of any kind of engagement in public
health and only interested in medicines that produce quick
and high turn over and profits by targeting pathologies
affecting larger populations in rich countries. In congresses,
meetings, scientific and extra scientific publications aired
during the first years of the AIDS pandemic it was repeat-
edly stated that because AIDS affected a much smaller
number of people than other pathologies and since in most
of the HIV infected people income levels were low, the
pharmaceutical corporations would be of little help. However,
the enhancement of survival and quality of life and the
reduction in physical and mental suffering was made possible
by those from whom less was expected (while the big delu-
sion came from those from whom much was expected!).
Finally, the purpose of presenting the concatenation of
events that changed the life expectancy of HIV-infected
people is neither to be trapped by indulgent and easy diatribes
nor to put forth ideological pamphlet arguments that could
have been drafted in the absence of proven evidence. Because
the fight against AIDS shows a positive corollary, the assign-
ment of blame to any particular establishment or individual
may apparently have no impact. However, it appears that
the presentation of questions for sustaining the future of good
intentions and adroit decisions is salutary and that the dia-
lectic analysis should be read as a prophylactic a posteriori
auto critic, never pointing out faithlessness, inefficiency,
prejudices, disorientation or misguidance. Therefore, the
events that occurred between 1985 and 1997 should teach
us how not to shape the appropriate strategies to face future
emergent health crises without ruining good intentions,
keeping in mind the crying need to push research policies
forward because cancer is still killing massively, and politi-
cians, media managers and fund raisers become agitated
with the potential relevant returns of human distress.
In a regulated framework which respects universal
ethical standards and free access to health care, a paradox
was created by a “revolutionary” change operating in the
management of HIV infection as a consequence of the speedy
and efficient contribution from the private pharmaceutical
sector. Because antiviral therapeutics have largely proven to
reduce the fatal prognosis due to HIV, it still remains our
urgent duty to share the success of the pharmacological
strategies with our peers in countries with limited resources
and with fellows living in industrialized countries, which,
whether due to their socio-cultural, affective or educational
situation require additional caring and dedicated efforts for
education.